Seeking Alpha

LT

LT
Send Message
View as an RSS Feed
View LT's Comments BY TICKER:
Latest  |  Highest rated
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]
    FBR Capital analyst Christopher James reiterated an Outperform rating and $8 price target on CytRx Corp (NASDAQ: CYTR) saying today's Phase Ib combination data "look promising."

    James commented, "This morning, CytRx Corporation (CYTR) reported favorable data from two ongoing combination Phase Ib studies.

    The studies, which pair escalating doses of aldoxorubicin with standard doses of either gemcitabine or ifosfamide, showed impressive tumor responses and adequate tolerability in patients with osteosarcoma (bone cancer) and a variety of soft-tissue sarcomas (STS).

    We believe the data highlights aldoxorubicin's compatibility with other oncology therapies and reinforces our view of the drug's future role in the treatment of multiple cancer indications.

    We think the data from these small open-label studies are encouraging and provide validation for the advancement into larger blindedrandomized studies."
    For an analyst ratings summary and ratings history on CytRx Corp click here. For more ratings news on CytRx Corp click here.
    Shares of CytRx Corp closed at $3.70 yesterday.
    Copyright 2015, Street Insider News Provided by Acquire Media Corporation
    May 4, 2015. 04:39 PM | 2 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]
    you know I am going to stay n play, just not going to play nearly as much.

    -this is the time of year stocks go down on good news
    -not big bubble burst, but 100's of tiny bubbles burst
    -cant appease Wall st with earnings no matter how good they are...ex. APPLE
    -most co's are guiding weaker so they can easily beat earnings
    plus I don't like all the micro things going on..Greece, Syria, Yemen, Russia/Ukraine, Africa, not to mention our dysfunctional gov't. No one of these is huge, but ramifications can send shock waves.
    -interest rates, someday the fed will raise even tho the economic numbers and the EZ won't justify it. Wall St is looking for any reason for a big 10-20% correction so they'll have their temper tantrum .... if they think free money is over we may or may not make or sustain new highs, then the 2016 election is another wall of worry right behind that. Yes, I'm pretty negative right now.

    I still have my long term holds, and muni's, and have raised cash to buy when/if something drops that I like. I am not big enuff or smart enuff to play foreign currency & stocks ...so I'll just watch and maybe get lucky once in a while.
    May 4, 2015. 02:41 AM | 4 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]

    Exit continues from U.S. stock funds
    Another $4.5B was pulled from U.S. equity funds for the week ended April 29, the 10th outflow in the last 11 weeks, according to BAML and EPFR Global.

    Leading the exodus was the iShares Russell 2000 ETF (NYSEARCA:IWM) with $722M, followed by the SPDR DJIA Trust (NYSEARCA:DIA).

    The money isn't going under mattresses, but instead international funds have been seeing big inflows this year. Those inflows slowed to a crawl last week however, with just $400M entering European funds - the lowest level in 15 weeks.

    As for fixed-income, junk bonds have been the year's best performers, but funds holding them saw $600M in outflows last week - the most in 14 weeks.

    The iShares High Yield Corporate Bond ETF (NYSEARCA:HYG) suffered $702M in outflows just by itself.Source: Barron'sPreviously: High-yield leads fixed income in 2015 (May 1)
    May 3, 2015. 11:24 AM | 3 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]

    Adaptimmune Therapeutics on deck for IPO
    Oxfordshire, UK-based Adaptimmune Therapeutics (Pending:ADAP) is set for its IPO of 9.375M American Depositary Shares at $15 - 17.The clinical stage biopharmaceutical firm develops cancer immunotherapies based on its T-cell receptor platform, which identifies cancer targets (peptides), genetically engineers T-cell receptors (TCR) and then produces the therapeutic candidates for administration to patients.
    According to the company, the breadth of targets for TCR therapies is greater than those based on chimeric antigen receptor T cells (CAR-Ts) because the TCRs target both intracellular and extracellular cancer antigens. CAR-Ts, which genetically engineer T cells to produce chimeric antigen receptors on their surface, are extracellular only.

    Its lead program is the Phase 1/2-stage NY-ESO, a TCR therapy for the potential treatment of solid tumors, blood cancers, ovarian cancer and esophageal cancer.

    In a synovial cancer study, six of 10 patients who received NY-ESO-TCR responded, one complete (before relapsing nine months later) and five partial.

    In a study of multiple myeloma following autologous stem cell transplant, 13 of 22 patients with active disease at time of transplant experienced complete or near-complete responses at 100 days post administration.

    Additional data will be reported later this year.Financials (six-month period ending Dec. 31 2014) ($M): Revenues: 3.8 (+55.8%); Net Loss: (4.8) (-55.8%); Cash Burn: (15.2) (-55.8%).
    May 2, 2015. 04:27 AM | 3 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]

    Chevron needs to boost cash flow to cover its dividend, CFO says
    Chevron's (CVX -1.9%) top priority is maintaining a dividend that’s “competitive and growing,” CFO Patricia Yarrington said in today's earnings conference call, but WSJ's Maxwell Murphy writes that the company needs a surge in cash flow to maintain its dividend and capital spending.In its Q1 earnings report, CVX said its operating cash flow was $2.3B - less than a quarter of its combined capex and dividend; the company's $33.9B debt now tops that of rival Exxon (NYSE:XOM) even though CVX has roughly half the annual revenue.Yarrington said CVX will take a multi-pronged approach to generating enough cash, boosting cash flow through production growth while trimming its cost structure and capex budget, and selling assets; she said CVX had disposed of $10B in assets over the past 16 months, putting it well on track to achieve its $15B four-year plan.
    | 3:57 PM|12 Comments
    May 2, 2015. 04:20 AM | 2 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]
    Here's my fave list with my thoughts and possible entry points. keep in mind most of these are way away from an approved drug, but have very promising tech......I was lucky to have taken money off the table, these raises caught me off guard as well as the entire bio fall out. Just shows they got way too far ahead of themselves vs. stock price/drug to mkt approval dates. NVAX & INO are much further down the road to approval but even they are a couple of years away.

    BIOD high of $1.32 trading now at $1.13 has been lower. I call this a buy and hold now. I have a full position with a higher cost basis than todays price.

    CYTR high $5.29 now $3.70 scale in buy now. I took some profits, but still have a cost basis higher than today ... I'll double down soon. but in no hurry.

    INO high over $10.60 now at $8.40 buy under $8. I own 2000 shares of this, not hurt by the funding drop, but my ego is. The mgt needs to get it's act together here and move forward and quit the games. Remember the Gates family funded this, so IMO that's who pushed this last huge deal thru and thats definitely an overhanging weight.

    NVGN high $9.27 now at $5.91 buy here or on weakness. I took profits on the big chunk, still have $3000 shares. Cost basis isn't bad for me, but another hit to my ego. I would buy on any further drop here.

    There's a few others, like ADXS (advaxis) but it skyrocketed on the heels of ADRO new IPO, so it's way out of kilter or the tech is better than we think. they are down from over $22 to $16 now... I sold my last shares at over $21 and don't know where I'll buy back. Remember not many months ago it was a $1.60 stock, then rallied to $6 and then soared to over $20.
    Its a wild ride.
    May 1, 2015. 02:54 PM | 6 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]

    Advaxis prices equity offering
    Advaxis (ADXS -8.1%) prices its public offering of 2.8M shares of common stock at $19 per share. Underwriters over-allotment is an additional 420K shares. Closing date is May 5. Net proceeds will fund R&D and general corporate purposes.

    |11:57 AM|2 Comments
    May 1, 2015. 03:49 AM | 5 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]

    Inovio prices equity offering
    Inovio Pharmaceuticals (INO -17.3%) prices its public offering of 9.5M shares of common stock at $8 per share. Underwriters over-allotment is an additional 1.425M shares. Closing date is May 5. Net proceeds will be used for general corporate purposes.

    | 1:28 PM|6 Comments
    May 1, 2015. 03:49 AM | 5 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]
    IMO, buying opportunities are approaching quickly with the severity of the bio sell off.

    After the dust settles from these capital raises I am going back into my basket again, and re-establish positions.
    Apr 30, 2015. 09:49 PM | 5 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]
    Everything got creamed today, with little hope on the horizon,
    too many things like Greece, earnings and low guidance.

    Linked-In down 25% in AH trades on weak outlook. This mkt has been a shorts dream. I sure wish I had nerve.
    Apr 30, 2015. 09:47 PM | 3 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]
    MJ, i too like your "scaling in" aproach. IMO there is plenty of time, but I will begin to scale in as soon as this mkt settles down.
    Apr 30, 2015. 02:13 PM | 4 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]

    Banks and insurers outperform as rates head higher
    The major averages are lower by 0.5% or more, but margin-starved financials are in the green as rates head higher both here and overseas.

    Previously: Major selloff in fixed income (April 29)The 10-year U.S. Treasury yield is up six basis points to 2.06% - nearing its highest level of the year -

    and European yields are shooting up even faster ... All this despite the absence of any GDP growth in the U.S. in Q1.Considered perhaps the most "asset-sensitive" of the TBTF banks, Bank of America (BAC +1.9%) is leading that group higher.Among regional names: Regions Financial (RF +1.1%), Fifth Third (FITB +1.3%) SunTrust (STI +0.9%), BB&T (BBT +0.8%).Insurers: MetLife (MET +2.4%), Prudential (PRU +1.5%), Lincoln National (LNC +1.8%).
    Apr 30, 2015. 05:51 AM | 4 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]

    Biotechs continue slide
    The biotech sector heads south again today, continuing the move that began in earnest on Monday. The iShares Biotechnology ETF, for example, is down over 8% from the March 29 high of 374.97 and down almost 7% from the intermediate high of 368.25 on April 23. This phase of the down move is particularly bearish considering the high volume driving the drops on Monday and Tuesday (2.3x normal volume both days).A correction is not that surprising in light of the uninterrupted one-year uptrend. On a technical basis, IBB longs should look for support at 320.ETFs: IBB, BIB, BIS
    Apr 30, 2015. 05:49 AM | 3 Likes Like |Link to Comment
  • Swine Flu, MERS, Ebola And Medical News Concentrator January 1, 2015 To May 23, 2015 [View instapost]
    by the way, Advaxis ADXS is doing the same thing.
    Apr 30, 2015. 04:33 AM | 4 Likes Like |Link to Comment
  • QuickChat #280, April 16, 2015 [View instapost]
    Worth watching for all co's,,,Apple also put out an official release saying this could affect profits and cash significantly if they lose it. FYI, it goes back 10 years. Combine this with the euro drop and it's huge.

    I look for this to be the trend globally, too much cash parked.


    In its FQ2 10-Q, Apple discloses the European Commission "could require Ireland to recover from the Company past taxes covering a period of up to 10 years," and that such tax payments could be "material." The EC has long been probing the use of Irish legal structures by Apple and other U.S. multinationals to lower their local tax bills; the FT reported last year Apple could receive a fine of up to several billions of euros.
    Apr 30, 2015. 04:32 AM | 5 Likes Like |Link to Comment
COMMENTS STATS
5,558 Comments
273 Likes